The table below indicates the characteristics of patients included in the FOXFIRE Combined Analysis. There were no significant differences in baseline patient characteristics. A majority of patients had poor prognostic factors at baseline: almost 90% of patients had synchronous disease, more than half of the patients had primary tumour in situ and more than a third of the patients had extra-hepatic metastases.
Now leaving sirtex.com
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
Now leaving sirtex.com
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes
no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
You are now leaving your current sirtex.com region
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
This content is intended for healthcare professionals only
By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.
Go to Homepage
Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and
unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.